"Dec. 5, 2014 -- Children with asthma might one day benefit from a simple urine test that could ensure they receive the right dose of medication to help them better manage their condition.
An Anglo-Polish research team found that a urine tes"...
Tilade Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Tilade (nedocromil inhalation) is an inhaled anti-inflammatory agent used alone or with other medications to prevent symptoms (wheezing, cough, and shortness of breath) caused by asthma. Common side effects include dry mouth, unpleasant taste, itchy skin, or mild nausea.
The dose of Tilade is two inhalations four times a day at regular intervals, which provides a dose of 14 mg per day. Tilade should be orally inhaled only in patients age 6 years and older. Tilade may interact with other drugs. Tell your doctor all medications and supplements you take, especially other medications to treat asthma. During pregnancy, Tilade should be used only when prescribed. It is not known if Tilade passes into breast milk. Consult your doctor before breastfeeding.
Our Tilade (nedocromil inhalation) Side Effects Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
What is Patient Information Overview?
A concise overview of the drug for the patient or caregiver from First DataBank.
Tilade Overview - Patient Information: Side Effects
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Tilade (Nedocromil Inhalation Aerosol)»
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Tilade FDA Prescribing Information: Side Effects
Tilade (nedocromil inhalation aerosol) is generally well tolerated. Adverse event information was derived from 6,469 patients receiving Tilade (nedocromil inhalation aerosol) in controlled and open-label clinical trials of 1-52 weeks in duration. A total of 4,400 patients received two inhalations four times a day. An additional 2,069 patients received two inhalations twice daily or another dose regimen. Seventy-seven percent of patients were treated with Tilade (nedocromil inhalation aerosol) for eight weeks or longer.
Of the 4,400 patients who received two inhalations of Tilade (nedocromil inhalation aerosol) four times a day, 2,632 were in placebo-controlled, parallel trials and of these 6.0% withdrew from the trials due to adverse events, compared to 5.7% of the 2,446 patients who received placebo.
The reasons for withdrawal were generally similar in the Tilade (nedocromil inhalation aerosol) and placebo-treated groups, except that patients withdrew due to bad taste statistically more frequently on Tilade (nedocromil inhalation aerosol) than on placebo. Headache reported as severe or very severe, some with nausea and ill feeling, was experienced by 1.0% of Tilade (nedocromil inhalation aerosol) patients and 0.7% of placebo patients.
The events reported with a frequency of 1% or greater across all placebo-controlled studies are displayed for all patients ages 6 years and older who received Tilade (nedocromil inhalation aerosol) or placebo at two inhalations four times daily.
The adverse event profile observed in children ages 6 through 11 was similar to that observed in adults.
|% Experiencing AE||% Withdrawing|
|ADVERSE EVENT (AE)||Tilade
|Respiratory System Disorders|
|Upper Respiratory Infection||6.7%||6.3%||0.1%||0.2%|
|Central and Peripheral Nervous System|
|Body as a Whole|
|Resistance Mechanism Disorders|
|Skin and Appendages Disorders|
|* Statistically significant higher frequency on Tilade (nedocromil inhalation aerosol) , p<0.05
**Statistically significant higher frequency on Placebo, p<0.05
Other adverse events present at less than the 1% level of occurrence, but that might be related to Tilade (nedocromil inhalation aerosol) administration, include arthritis, tremor, and a sensation of warmth. In clinical trials with 2,632 patients receiving Tilade (nedocromil inhalation aerosol) , 2 patients (0.08%) developed neutropenia and 3 patients (0.11%) developed leukopenia. Although it is unclear if these reactions were caused by Tilade (nedocromil inhalation aerosol) , in several cases these abnormal laboratory tests returned to normal when Tilade (nedocromil inhalation aerosol) was discontinued.
There have been reports of clinically significant elevation of hepatic transaminases (ALT and AST greater than 10 times the upper limit of the normal reference range in one patient) associated with the administration of Tilade (nedocromil inhalation aerosol) . It is unclear if these abnormal laboratory tests in asymptomatic patients were caused by Tilade (nedocromil inhalation aerosol) .
Cases of bronchospasm immediately following dosing with Tilade (nedocromil inhalation aerosol) have been reported from postmarketing experience. (See WARNINGS.) Isolated cases of pneumonitis with eosinophilia (PIE syndrome) and anaphylaxis have also been reported in which a relationship to drug is undetermined.
Read the entire FDA prescribing information for Tilade (Nedocromil Inhalation Aerosol) »
Additional Tilade Information
Tilade - User Reviews
Report Problems to the Food and Drug Administration
Allergies & Asthma
Improve treatments & prevent attacks.